Jamei Masoud, Turner David, Yang Jiansong, Neuhoff Sibylle, Polak Sebastian, Rostami-Hodjegan Amin, Tucker Geoffrey
Modelling and Simulation Group, Simcyp Limited, Blades Enterprise Centre, John Street, Sheffield, S2 4SU, UK.
AAPS J. 2009 Jun;11(2):225-37. doi: 10.1208/s12248-009-9099-y. Epub 2009 Apr 21.
The bioavailability of drugs from oral formulations is influenced by many physiological factors including gastrointestinal fluid composition, pH and dynamics, transit and motility, and metabolism and transport, each of which may vary with age, gender, race, food, and disease. Therefore, oral bioavailability, particularly of poorly soluble and/or poorly permeable compounds and those that are extensively metabolized, often exhibits a high degree of inter- and intra-individual variability. While several models and algorithms have been developed to predict bioavailability in an average person, efforts to accommodate intrinsic variability in the component processes are less common. An approach that incorporates such variability for human populations within a mechanistic framework is described together with examples of its application to drug and formulation development.
口服制剂中药物的生物利用度受多种生理因素影响,包括胃肠液成分、pH值和动力学、转运和蠕动,以及代谢和转运,其中每一项都可能随年龄、性别、种族、食物和疾病而变化。因此,口服生物利用度,尤其是难溶性和/或低渗透性化合物以及那些被广泛代谢的化合物的口服生物利用度,常常表现出高度的个体间和个体内变异性。虽然已经开发了几种模型和算法来预测普通人的生物利用度,但考虑组成过程中内在变异性的努力却不太常见。本文描述了一种在机制框架内纳入人群此类变异性的方法,并举例说明了其在药物和制剂开发中的应用。